Gelmetix

The company's lead product, DXM, is a minimally invasive, injectable hydrogel for treating chronic lower back pain caused by degenerative disc disease. Delivered in a single injection, DXM works by supplementing and rehydrating the nucleus pulposus—the core of the intervertebral disc—to restore its function, relieve pain, and potentially slow the degenerative process. This approach is positioned as a treatment option between conservative pain management, like opiate-based medication, and major surgery. The company has received approval from the French regulator (ANSM) to commence first-in-human trials.

Gelmetix's business model focuses on developing and commercializing its portfolio of biomaterial medical devices. The company has secured significant funding through multiple rounds, including a £1.2 million Series B in 2018 and a £5 million Series C in 2021, to advance its clinical trials and prepare for commercial launch. Beyond back pain, Gelmetix is developing its technology platform for other applications, including treating osteoarthritis in small joints (SXM product) and as a carrier for regenerative agents like stem cells.